Haemonetics Corporation 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Haemonetics Corporation on April 27, 2026. The report discloses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel matter and contains no financial data.
Material Changes
On April 27, 2026, Charles J. Dockendorff informed the Company that he will not stand for re-election at the 2026 Annual Meeting of Shareholders. Mr. Dockendorff has served on the Board since 2014 and is a member of the Audit Committee and the Governance and Compliance Committee. He will continue to serve in these roles until the Annual Meeting. The filing explicitly states that this decision is not the result of any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the standard disclosure of the director's departure.
Key Facts for Investors to Verify
- Charles J. Dockendorff will not seek re-election at the 2026 Annual Meeting.
- Mr. Dockendorff remains on the Board and his committees until the meeting concludes.
- The departure is voluntary and not due to any disagreement with the Company.
- The Company has not announced a replacement nominee in this filing.